- Infrastructure Stocks Slide After Manchin Rejects Biden’s Plan
Keep an eye on :
- BOL FP : Bollore Is in Talks to Sell African Logistics for $6.4 Billion
* Straumann Raised to Outperform at Bernstein
>>> Down
* BillerudKorsnas Cut to Hold at ABG; PT 175 kronor
>>> Initiation
* Petrofac Coverage Dropped by Morgan Stanley
>>> Call
* TUI New Hold at Peel Hunt, Recovery Potential With Uncertainties
- Evergrande Declared in Default by S&P for Failed Payments
- Evergrande Land Seized by Chengdu City on Lack of Development:
- China Offshore Bond Defaults Hit Record in December
- China Regulators Encourage Property Acquisitions
- Kaisa Appoints Advisers; Shares Resume Trading
- Evergrande Backer’s Privatization Collapses
- Shimao Sells Stake in Hong Kong Development Z
- The combination of elevated inflation and renewed growth concerns from the spread of the omicron variant of Covid has complicated the job of policy makers around the world. While the Fed and other major central banks have shifted focus to taming inflation, markets are more nervous about the economic outlook. For instance, the market implied rate for the Fed’s benchmark in 2023 has declined since the FOMC meeting last week to about 1.25%, compared with the median forecast of 1.625% on the dot- plot.
- In contrast, Beijing, with less inflation pressure, is moving toward policy easing. Chinese banks cut the one-year LPR rate by 5 bps Monday, surprising most economists who had expected them to stay put. But market reactions were largely muted. Ten-year bond yields were little changed, while the CSI 300 declined 1.5%. What gives?
- For starters, while few economists had predicted the move, investors have been anticipating some policy easing since the central economic working conference earlier this month, when Beijing signaled that propping up the economy has become its top priority. The RRR cut in early December, plus a similar move in July, saved enough costs for banks to pass them on to borrowers. So the LPR cut did not exactly come out of the blue.
- The lenders held the five-year rate, which is tied to mortgage rates, steady. It signaled that Beijing may not intend to change overall control over the housing market, despite some recent policy fine-tuning. What’s more, the seven-day repo, a measure of interbank liquidity, has been stable. All of this suggests that the PBOC isn’t in a full-blown easing mode, yet.
- Historically, the stock, bond and currency markets’ performance has been mixed in the month following an LPR cut. As noted by Larry Hu, an economist at Macquarie Securities, cutting the rate is less important in China’s context, “where the monetary policy is more based on quantity than price.” In other words, the supply of money is more important than the price of money.
closing Stock Market SummaryThe S&P 500 fell 1.1% on Monday amid pestering growth concerns, although the benchmark index was down as much as 1.9% intraday. The Nasdaq Composite (-1.2%) and Dow Jones Industrial Average (-1.2%) both declined 1.2% while the Russell 2000 lagged with a 1.6% decline.
Growth concerns were driven by new COVID restrictions in Europe, word from Senator Manchin (D-WV) that he won't support the $1.75 trillion Build Back Better Act, and a view that the Fed could be tightening policy at an inopportune time next year.
Sellers maintained control of the market until shortly after the close of European markets (11:30 a.m. ET). Buyers stepped in, spying a good entry point with the S&P 500 trading below its 50-day moving average (4608) and down as much as 4.3% from its intraday high last Thursday.
The S&P 500 still closed below that key technical level, but two of its 11 sectors did sneak into positive territory, namely utilities (+0.1%) and consumer staples (+0.04%). The cyclical financials (-1.9%), materials (-1.8%), industrials (-1.7%), and consumer discretionary (-1.7%) sectors closed sharply lower.
Moderna (MRNA 276.38, -18.42, -6.3%) fumbled a 9% gain, and closed lower by 6%, even though the company announced encouraging preliminary data for its COVID-19 booster shots. Oracle (ORCL 91.64, -4.98, -5.2%) fell 5% on confirmation of its acquisition of Cerner (CERN 90.49, +0.72, +0.8%) for $95.00/share in cash, or approximately $28.3 billion in equity value.
Elsewhere, a steepened Treasury yield curve signaled a more constructive perspective. The 10-yr yield increased two basis points to 1.42% after trading at 1.35% overnight. The 2-yr yield decreased two basis points to 0.62% amid a view that the Fed could still lean cautiously next year given the economic uncertainty of the Omicron variant.
WTI crude futures fell 3% ($68.66/bbl, -2.27, -3.2%) on expectations for weaker demand amid tighter economic restrictions. The U.S. Dollar Index decreased 0.1% to 96.51. The CBOE Volatility Index closed higher by 6.0% at 22.87 after topping 27.00 intraday.
Monday's economic data was limited to the Conference Board's Leading Economic Index (LEI), which increased 1.1% in November ( consensus 1.0%) following a 0.9% increase in October. Looking ahead, investors will receive the Currant Account Balance for the third quarter on Tuesday.
- S&P 500 +21.6% YTD
- Nasdaq Composite +16.2% YTD
- Dow Jones Industrial Average +14.1% YTD
- Russell 2000 +8.3% YTD
After Hours Summary: MU +7% rises on earnings/guidance while ALDX -32% falls on results from Phase 3 TRANQUILITY trialAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: MU +6.7%, BRZE +5.9%, NKE +3.7%
Companies trading higher in after hours in reaction to news: ACAD +5.2% (announced plans to resubmit sNDA for NUPLAZID), PSN +4.1% (awarded $38 mln Army task order), FTAI +2.7% (submitted documentation with respect to potential spin-off of infrastructure business), HAYW +2% (approved new $450 mln stock repurchase program), BDSI +1.8% (announced favorable opinion in patent litigation against Alvogen Group), JBL +1.3% (announced new manufacturing partnership with Carnival [CCL]), AMGN +1.3% (announced FDA approval of OTEZLA as treatment for plaque psoriasis)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: CVGW -2.7%
Companies trading lower in after hours in reaction to news: ALDX -32% (announced top-line results from Phase 3 TRANQUILITY trial in dry eye disease; primary endpoint of ocular redness was not met), CTMX -19.8% (announced preliminary results from Phase 2 expansion study of CX-2029 in patients with sqNSCLC or HNSCC), DBVT -14.8% (announced plans to initiate new Phase 3 clinical study for modified Viaskin Peanut patch and to withdraw the MAA for Viaskin Peanut in Europe)




